The in vivo data in Supplementary Figure 13 confirms prior in vivo studies using lapatinib and afatinib in combination with [pemetrexed + sorafenib], demonstrating that transient inhibition of ERBB1/2/4 significantly reduced tumor growth in the presence of [pemetrexed + sorafenib]. Here, EGFR is linked to neoplasm.